Abrax Japan’s co-founder, Dr. Taku Kambayashi won the First Place Prize at both the STAT Breakthrough Science Summit 2022 and the STAT Madness bracket competition.
Dr. Taku Kambayashi, co-founder and Chief Science Advisor (CSA) of Abrax Japan, Inc. won the First Place Prize for his breakthrough discovery at a special competition event called “STAT Madness”, which was a part of “STAT Breakthrough Science Summit 2022”, held in New York City on March 31, 2022.
STAT Madness is an annual bracket-style competition that highlights some of the most notable biomedical research from the past year. This year’s STAT Madness nominated 64 topics of the most noteworthy scientific and medical breakthroughs published in 2021, from which industry leaders selected the most cutting-edge innovations to pay attention to. Dr. Kambayashi was awarded with the First Place Prize in both categories (STAT Madness Bracket Win and Breakthrough Science Summit) with a substantial margin of victory for his groundbreaking research on the potential therapeutic application of a cytokine called thymic stromal lymphopoietin (TSLP), which was published in the journal Science in July 2021.
Commenting on this outstanding accomplishment, Jo Narita, co-founder and CEO of Abrax Japan Inc. expressed his excitement. “We are extremely pleased to have presented Dr. Kambayashi’s research results at this fantastic STAT Madness event and to have received the highest recognition of the First Place Prize. The pioneering research presented here is just the small beginning of what Dr. Kambayashi and Abrax Japan are creating for the future of breakthrough therapies, and we will continue to move forward to commercialize the results of our research.
The articles about the two wins on the special “STAT Madness” event at the STAT and Breakthrough Science Summit 2022 can be found at the links below on the official STAT website.
For more information on this topic, please contact Abrax Japan, Inc.
